Clinical Trials Logo

Heart Septal Defects, Atrial clinical trials

View clinical trials related to Heart Septal Defects, Atrial.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04395027 Withdrawn - Clinical trials for Septal Defect, Atrial

Iatrogenic Atrial Septal Defect Study (iASD)

iASD
Start date: May 6, 2020
Phase: Phase 3
Study type: Interventional

This is an open-label, randomized, controlled trial of iatrogenic atrial septal defect closure with the an atrial septal occluder versus usual care observation in patients post-mitral valve intervention requiring large bore transspetal access.

NCT ID: NCT03867708 Withdrawn - Clinical trials for ASD2(Secundum Atrial Septal Defect)

Outcomes of Transcatheter ASD Closure Guided by 3D-TEE

Start date: December 2020
Phase:
Study type: Observational

Atrial Septal Defect (ASD) is a common cardiac diagnosis among adults.Three-dimensional transesophageal echocardiography (3D-TEE) improve the visualization of ASD, its rims and surrounding structures and can be used for guidance during percutaneous transcatheter closure. Proper device size selection is important for success of ASD device closure. 3D-TEE can assess the ASD morphology, maximal diameter, area and determine the device size without balloon sizing during percutaneous closure.There are some adverse outcomes reported in previous studies following transcatheter secundum ASD closure as: residual shunt, new onset atrial fibrillation(AF) and mitral regurgitation(MR)deterioration . These adverse outcomes are responsible for morbidity and mortality following transcatheter ASD closure, so it is essential to study risk factors associated with these adverse outcomes in order to minimize their incidence.The investigators will study the role of 3D-TEE in proper device size selection, also the percentage and predictors of adverse outcomes after device closure guided by 3D-TEE.